within Pharmacolibrary.Drugs.ATC.S;

model S01FB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.0012,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.158,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0011666666666666668,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01FB03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ibopamine is a synthetic dopamine prodrug, previously used as a cardiovascular agent with positive inotropic and vasodilatory properties, primarily for the treatment of congestive heart failure and occasionally in ophthalmology for pupil dilation. However, it is not widely approved and has largely been withdrawn from clinical use in many countries.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for ibopamine in adult healthy subjects due to lack of published direct PK data. Ibopamine is known to be rapidly hydrolyzed to epinine, the active metabolite, after oral administration.</p><h4>References</h4><ol><li><p>Itoh, H (1991). Clinical pharmacology of ibopamine. <i>The American journal of medicine</i> 90(5B) 36S–42S. DOI:<a href=&quot;https://doi.org/10.1016/0002-9343(91)90272-y&quot;>10.1016/0002-9343(91)90272-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1675550/&quot;>https://pubmed.ncbi.nlm.nih.gov/1675550</a></p></li><li><p>de Mey, C, et al., &amp; Wesche, H (1988). Pharmacokinetics and pharmacodynamics of single oral doses of ibopamine, quinidine and their combination in normal man. <i>European journal of clinical pharmacology</i> 34(4) 415–418. DOI:<a href=&quot;https://doi.org/10.1007/BF00542446&quot;>10.1007/BF00542446</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3402527/&quot;>https://pubmed.ncbi.nlm.nih.gov/3402527</a></p></li><li><p>Ogawa, R, et al., &amp; Echizen, H (2014). Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally). <i>Clinical pharmacokinetics</i> 53(12) 1083–1114. DOI:<a href=&quot;https://doi.org/10.1007/s40262-014-0189-3&quot;>10.1007/s40262-014-0189-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25248847/&quot;>https://pubmed.ncbi.nlm.nih.gov/25248847</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01FB03;
